Physician profile
Marshall Morrison
NPI 1508836099
$6,279.78
in general payments reported to CMS, 2019-2025
50 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,175 · 2020: $920 · 2021: $1,289 · 2022: $1,139 · 2023: $1,190 · 2024: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,757.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,756.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $980.16 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $604.97 | 2019-2024 | Jardiance |
| Pfizer INC. | $568.96 | 2019-2024 | |
| Glaxosmithkline, LLC. | $551.67 | 2019-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals Lp | $448.78 | 2019-2022 | |
| Lilly USA, LLC | $365.76 | 2020-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $329.62 | 2019-2023 | Rybelsus, Ozempic |
| Astellas Pharma US INC | $221.38 | 2019-2024 | Myrbetriq, Veozah |
| Sunovion Pharmaceuticals INC. | $189.69 | 2019-2021 | |
| Antares Pharma, INC. | $150.64 | 2020-2023 | Nocdurna, Xyosted, Tlando |
| Mylan Specialty L.P. | $126.09 | 2019-2023 | Yupelri |
| Medicure Pharma INC. | $125.90 | 2020 | |
| Amgen INC. | $121.46 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $116.95 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $104.73 | 2019-2022 |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marshall Morrison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.